Sequence Bio announces the appointment of Dr. Michael S. Phillips as its new Chief Scientific Officer. The emerging data-driven biotechnology company is based in Newfoundland and Labrador. He comes equipped with over 25 years of experience in large-scale genomic projects, drug target discovery, and leading research teams. His most recent post was VP Genomics at Genomics Medicine Ireland.
“I am thrilled to be returning home to Canada to join Sequence Bio, an exciting new biotech company planning to use cutting-edge genomic technology and science to identify drug targets and disease biomarkers that have the potential to directly benefit the people of Newfoundland & Labrador in a real and meaningful way,” says Phillips.
Phillips has extensive expertise leading large research groups in Academia, Biotech, Pharma and Hospital settings for drug target discovery, biomarker research, clinical diagnostics, and technology development. His positions include roles at Merck & Co., Orchid BioSciences, Génome Québec, Université de Montréal, Montreal Heart Institute and Centre Hospitalier de L’Université de Montréal (CHUM) Research Centre. In his most recent role as VP Genomics at Genomics Medicine Ireland, Phillips was responsible for developing a state of the art clinical genomics laboratory, building highly skilled teams and contributing to the company’s scientific direction. He has published over 70 articles in leading peer-reviewed journals and delivered hundreds of international presentations on his work.
“We are incredibly proud to have Dr. Phillips and his international expertise with population genetics research projects join the team,” says Chris Garner, CEO of Sequence Bio. “He recognizes Sequence Bio’s unique opportunity to innovate drug discovery and embraces our participant-centric approach to benefit the people of Newfoundland & Labrador. We’re excited to strengthen our team with Dr. Phillip’s appointment.”
His role as the chief scientific officer will entail leading scientific development projects and genomic and precision medicine research for Sequence Bio. Specifically, he will be focusing on the NL Genome Project – a proposed large-scale genome sequencing project in the Newfoundland and Labrador genetic isolate founder population to drive novel therapeutic discovery and development.
Sequence Bio takes an unprecedented participant-centric approach to its research and discovery efforts by aiming to return findings to participants and better the province of Newfoundland and Labrador and the people and communities within. Dr. Phillips will be working with Dr. Gerald Mugford, Ms. Diane Power, and the rest of the team in maintain the highest standards for participant research, privacy, and ethical research behaviour.
BC biotech company AbCellera receives $1-M non-dilutive funding Next Post:
Good manufacturing practices in Canada